Last Updated: 09/10/2019
Cardio‑Safety of Dihydroartemisinin‑Piperaquine and Pharmacokinetics of Piperaquine Amongst Pregnant Women in Tanzania
Objectives
The aim of this project is to determine the cardio-safety of DP compared to SP amongst pregnant women in Tanzania since seems that DP will increase the time between the start of the Q wave and the end of the T wave in the heart’s electrical cycle, a phenomenon referred to as QT prolongation, in the study population.
London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom
Sulfadoxine-pyrimethamine (SP) is currently recommended by the World Health Organization for use as an intermittent preventive treatment against malaria in pregnancy (IPTp) in areas of moderate to high malaria transmission. However, in some locales malaria parasites have lost sensitivity to SP, compromising its protective effect. Dihydroartemisinin-piperaquine (DP) is a candidate replacement for SP.
ClinicalTrials.gov Identifier: NCT02909712
Study Phase: Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Basic Science
Drug-based Strategies
Impact of Interventions
Vulnerable Populations
Sep 2016 — Sep 2017
